{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:05:27Z","timestamp":1793675127524,"version":"4.5.1"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medical Council of Thailand","award":["2021"],"award-info":[{"award-number":["2021"]}]},{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University","award":["64004"],"award-info":[{"award-number":["64004"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2024,9,21]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The 0bjective is to compare treatment effects between undiluted autologous platelet-rich plasma (APRP) and autologous serum (AS) in patients with moderate-to-severe dry eye disease (DED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>A single-centre, randomised, double-masked, non-inferiority clinical trial was conducted. 96 adult DED patients with an Ocular Surface Disease Index (OSDI) Score of \u226523 and\/or Oxford staining grade of \u22652 were randomised to receive either 100% APRP (n=48) or 100% AS (n=48) for 4 weeks. Primary outcomes included OSDI Score and ocular surface staining measured by Oxford grading scale at 4 weeks. Secondary outcomes included fluorescein tear break-up time, Schirmer\u2019s test, meibum quality and expressibility, and adverse events. The 95% CI for the mean difference in OSDI scores between groups was estimated to assess non-inferiority of the OSDI score at a prespecified margin of 4.18 points.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 4, there was no significant difference in decreased OSDI scores between groups, with the mean difference (100% APRP\u2212100% AS) of 1.41 (95% CI \u22121.26, 4.08, p=0.299). The upper limit was less than the prespecified margin, indicating non-inferiority of 100% APRP vs 100% AS. The probabilities of achieving an Oxford grade 0\u20131 after treatment were not significantly different between groups, with an OR of 0.61 (95% CI 0.25, 1.52, p=0.288). No significant differences in secondary outcomes were observed between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In the short-term, 100% APRP was not inferior to 100% AS in reducing dry eye symptoms and ocular surface staining in moderate-to-severe DED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04683796\">NCT04683796<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2024-001857","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T23:20:24Z","timestamp":1728429624000},"page":"e001857","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct04683796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04683796","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-2353","authenticated-orcid":false,"given":"Passara","family":"Jongkhajornpong","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Mahidol University Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-4581","authenticated-orcid":false,"given":"Kaevalin","family":"Lekhanont","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Mahidol University Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasivimol","family":"Rattanasiri","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Mahidol University Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawin","family":"Numthavaj","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Mahidol University Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"McKay","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[{"name":"Centre for Clinical Ophthalmology and Biostatistics and School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"Department of Medicine, John Hunter Hospital, University of Newcastle Hunter Medical Research Institute, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Mahidol University Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"2025090109535742000_9.1.e001857.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"2025090109535742000_9.1.e001857.2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"2025090109535742000_9.1.e001857.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"2025090109535742000_9.1.e001857.4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.transci.2017.07.023","article-title":"Blood derived eye drops for the treatment of cornea and ocular surface diseases","volume":"56","author":"Giannaccare","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"2025090109535742000_9.1.e001857.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270415"},{"key":"2025090109535742000_9.1.e001857.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-012-0175-y"},{"key":"2025090109535742000_9.1.e001857.7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","article-title":"Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study","volume":"6","author":"Alio","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"2025090109535742000_9.1.e001857.8","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0876"},{"key":"2025090109535742000_9.1.e001857.9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/ICO.0000000000002943","article-title":"Short-term Efficacy and Safety of Biological Tear Substitutes and Topical Secretagogues for Dry Eye Disease: A Systematic Review and Network Meta-analysis","volume":"41","author":"Jongkhajornpong","year":"2022","journal-title":"Cornea"},{"key":"2025090109535742000_9.1.e001857.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46671-2","article-title":"Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sj\u00f6gren\u2019s syndrome: a randomized trial","volume":"13","author":"Kang","year":"2023","journal-title":"Sci Rep"},{"key":"2025090109535742000_9.1.e001857.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-12879-x","article-title":"Comparison of epitheliotrophic factors in platelet-rich plasma versus autologous serum and their treatment efficacy in dry eye disease","volume":"12","author":"Metheetrairut","year":"2022","journal-title":"Sci Rep"},{"key":"2025090109535742000_9.1.e001857.12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093126","article-title":"The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome","volume":"12","author":"Wr\u00f3bel-Dudzi\u0144ska","year":"2023","journal-title":"J Clin Med"},{"key":"2025090109535742000_9.1.e001857.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048479","article-title":"Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol","volume":"11","author":"Jongkhajornpong","year":"2021","journal-title":"BMJ Open"},{"key":"2025090109535742000_9.1.e001857.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70081-2"},{"key":"2025090109535742000_9.1.e001857.15","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997a"},{"key":"2025090109535742000_9.1.e001857.16","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.2147\/OPTH.S265701","article-title":"Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review","volume":"14","author":"You","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"2025090109535742000_9.1.e001857.17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/ICU.0000000000000169","article-title":"Eye platelet-rich plasma in the treatment of ocular surface disorders","volume":"26","author":"Alio","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"2025090109535742000_9.1.e001857.18","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.044347"},{"key":"2025090109535742000_9.1.e001857.19","article-title":"Autologous serum eye drops for dry eye","volume":"2","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090109535742000_9.1.e001857.20","doi-asserted-by":"crossref","DOI":"10.1038\/srep38143","article-title":"Undiluted Serum Eye Drops for the Treatment of Persistent Corneal Epitheilal Defects","volume":"6","author":"Lekhanont","year":"2016","journal-title":"Sci Rep"},{"key":"2025090109535742000_9.1.e001857.21","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/521315","article-title":"Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery","volume":"2013","author":"Lekhanont","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025090109535742000_9.1.e001857.22","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.356"},{"key":"2025090109535742000_9.1.e001857.23","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200310000-00008"},{"key":"2025090109535742000_9.1.e001857.24","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1983.01040020385009"},{"key":"2025090109535742000_9.1.e001857.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2599-1"},{"key":"2025090109535742000_9.1.e001857.26","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2012.674609"},{"key":"2025090109535742000_9.1.e001857.27","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2012.720340"},{"key":"2025090109535742000_9.1.e001857.28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/02713683.2016.1255758","article-title":"Comparison of Autologous Serum Versus Preservative Free Artificial Tear in Patients with Dry Eyes Due to Systemic Isotretinoin Therapy","volume":"42","author":"Y\u0131lmaz","year":"2017","journal-title":"Curr Eye Res"},{"key":"2025090109535742000_9.1.e001857.29","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/aos.13907","article-title":"Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma","volume":"97","author":"Garc\u00eda-Conca","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"2025090109535742000_9.1.e001857.30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40778-016-0034-8","article-title":"Platelet-Rich Blood Derivatives for Stem Cell-Based Tissue Engineering and Regeneration","volume":"2","author":"Masoudi","year":"2016","journal-title":"Curr Stem Cell Rep"},{"key":"2025090109535742000_9.1.e001857.31","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/OPTH.S367807","article-title":"Autologous Platelet-Rich Plasma Drops for Evaporative Dry Eye Disease from Meibomian Gland Dysfunction: A Pilot Study","volume":"16","author":"Murtaza","year":"2022","journal-title":"Clin Ophthalmol"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2024-001857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:54:03Z","timestamp":1756745643000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2024-001857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,8]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/bmjophth-2024-001857"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2024-001857","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}